Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Keysight Technologies Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while Keysight Technologies Inc trades at $374.5 (market cap $64.93B). The key difference: Keysight Technologies Inc is far larger — about 11.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,517,176 versus 1,037,588). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Keysight Technologies Inc for 56 Days on average.
| IOVA | KEYS | |
|---|---|---|
Market Cap | $5.85B | $64.93B |
Volume | 14,517,176 | 1,037,588 |
Sector | Health | Technology |
52-Week High | $14.82 | $387.90 |
52-Week Low | $1.81 | $159.49 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $5.78B | $65.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Keysight Technologies (KEYS) trades at $374.66, down 3.41% on the day but remains in a bullish technical trend with strong analyst support. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 surpassing the $2.48 estimate. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
Outlook is positive driven by AI and 6G demand, but high valuation multiples pose a risk. The consensus price target of $416.63 implies 11% upside. Key risks include supply constraints and competitive pressures in the semiconductor testing space. Institutional sentiment remains bullish with 81% of analysts rating the stock a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
